Company News 

Novacyt transforms

Novacyt transforms

Novacyt (NCYT) experienced a “transformational” first half, in the words of chief executive Graham Mullis. This was not an exaggeration. Revenues for the France-based, Aim-traded clinical diagnostics group soared by more than 900 per cent to €72.4m (£63.3m) over the six months to June, with more than 91 per cent of that figure arriving in the second quarter alone. Meanwhile, cash profits are due to come in at more than €45m.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now